ArticleMedical oncology (Northwood, London, England)2011
Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 25 citations in OpenAlex.
- Trial
- Microtubule Acetylation Controls MDA-MB-231 Breast Cancer Cell Invasion through the Modulation of Endoplasmic Reticulum Stress.International journal of molecular sciences · 2021Article
- CRKII overexpression promotes theOncology letters · 2019Article
- Transcriptome analysis reveals the role of the PCP pathway in fipronil and endotoxin-induced lung damage.Respiratory research · 2019Article
- Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1.Scientific reports · 2018Article
- High co-expression of the SDF1/CXCR4 axis in hepatocarcinoma cells is regulated by AnnexinA7 in vitro and in vivo.Cell communication and signaling : CCS · 2018Article
- Correlation study between gene and respiratory disease in children.Experimental and therapeutic medicine · 2017Article
- Reversibility of regorafenib effects in hepatocellular carcinoma cells.Cancer chemotherapy and pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
c-Jun N-terminal kinase (JNK) is located in focal adhesion plaque (FAP). JNK is necessary to growth, morphogenesis, and differentiation of cells; especially JNK1 has a close relation with tumors. In this study, we silenced JNK1 by using short hairpin RNA (shRNA) and examined the effect on migration and invasion of mouse hepatocellular carcinoma (HCC) cell line Hca-F in vitro. Three shRNA expression vectors (JNK1shRNA-1, JNK1shRNA-2, and JNK1shRNA-3) were constructed and transfected to Hca-F cells stably. The most effective shRNA was selected by detecting the expression levels of mRNA and protein. Transwell assay was performed to detect the ability of migration and invasion of cells. A negative control sequence (JNK1shRNA control) and non-transfected normal Hca-F cells were treated as control groups. The "Results" showed that the expression vectors of pSilencer-JNK1shRNA were constructed and transfected to Hca-F cells successfully. The most effective shRNA was JNK1shRNA-2. The expressions of mRNA and protein of JNK1 in Hca-F cells after transfection of JNK1shRNA-2 were decreased significantly compared with the other groups (all, P<0.01; all, P<0.05). The ability of migration and invasion was decreased after down-regulation of JNK1 expression (all, P<0.05). These results suggest that the inhibition of JNK1 expression can decrease ability of migration and invasion of mouse hepatocellular carcinoma cell line in vitro. JNK1 plays an important role in lymphatic metastasis of HCC. It may be a new target for gene therapy of lymphatic metastasis of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.